SCHEMBL9866492

SCHEMBL9866492

CC(SCCNC(=O)N(S)C(=O)c1ccccc1)c1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
EPHX2 P34913 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.36
RECQL P46063 1/20 0.36
GPR139 Q6DWJ6 2/20 0.36
TRPM8 Q7Z2W7 1/20 0.36
ALDH1A1 P00352 3/20 0.35
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 2/20 0.35
CYP2C9 P11712 1/20 0.35
HPGD P15428 1/20 0.35
CYP2C19 P33261 1/20 0.35
LMNA P02545 2/20 0.35
MTNR1A P48039 2/20 0.35
MTNR1B P49286 2/20 0.35
MAPT P10636 1/20 0.35
TSHR P16473 1/20 0.34
TBXA2R P21731 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9866470 0.84 CYP1A2 (0.43) NPC1RAB9ASMN1; SMN2ALDH1A1CYP1A2
SCHEMBL9771234 0.81 DRD2 (0.49) TBXA2R
SCHEMBL28660632 0.77 MTNR1A (0.58) ALDH1A1MTNR1AMTNR1BMAPTTSHR
SCHEMBL9866486 0.73 ALDH1A1 (0.56) RAB9ASMN1; SMN2RECQLALDH1A1CYP1A2
SCHEMBL14859040 0.72 KDM4E (0.51) SMN1; SMN2ALDH1A1HPGD
SCHEMBL10365746 0.69 ACHE (0.64) CYP2C19LMNAMAPTTSHR
SCHEMBL11396142 0.68 SMN1; SMN2 (0.41) NPC1RAB9ASMN1; SMN2RECQLALDH1A1
SCHEMBL11404946 0.68 SMN1; SMN2 (0.41) NPC1RAB9ASMN1; SMN2RECQLALDH1A1
Iodide SCHEMBL9865687 0.68 SLC6A3 (0.33) SMN1; SMN2CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL14859856 0.68 RAB9A (0.56) NPC1RAB9AEPHX2SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5021431-A H-1 antagonist, h-2 agonist for treating hypertension, cardiac disease or arterial occlusion HEUMANN PHARMA GMBH & CO. (DE) 1991-06-04 US disclosed